NYSEMaterialsAgricultural InputsSnapshot 2026-08-31
Reading CTVA? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Warn: Primary pillar under pressure — Operating EBITDA remains between $4.0 billion and $4.2 billion: FY26 EBITDA guidance $4.1B-$4.3B vs $4.0B target.
Corteva grows seed and crop protection sales steadily. Operating EBITDA is guided near $4.1 billion in 2026. The planned seed business spin-off is on track for late 2026. New product partnerships boost crop protection revenue.
Pricing pressures and cost challenges could hurt margins. The spin-off may face delays or operational disruptions. Revenue growth is modest, near 4%, which may disappoint if costs rise.
The stock trades about 25% above our fair value near $69, reflecting roughly 4% revenue growth. Our fair value is 24% below the Street median, which is more optimistic. We see risk in margin and execution.
Breaks if: Crop Protection net sales fall below $1.78 billion
Breaks if: Operating EBITDA falls below $4.0 billion
Spin-off delayed beyond 2026-Q4
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround story with a medium confidence level. The current thesis state is watchful, as recent financial performance has been weak compared to peers.
The market seems to be pricing in a low level of fragility, but it is also stretched due to weak execution quality. There is a slight expectations gap, indicating that investors are not fully accounting for potential risks.
Management is on track with key priorities, including the planned separation and growth in the Seed segment. However, the recent financial performance has been weak, which could pose risks in the near term.
The thesis hinges on whether CTVA can maintain its guidance and avoid cutting expectations. Additionally, broader sector performance and inflation trends will be crucial for future momentum.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports a more favorable outlook. Additionally, the planned separation by 2026-Q4 reinforces confidence in the company's future. There are no new threats impacting the thesis at this time.
as of 2026-08-31
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Execute the spin-off of the seed business into an independent publicly traded company by the fourth quarter of 2026, including leadership appointments and regulatory filings.
Stated as a priority in 4 of last 4 quarters. Management consistently emphasized completing the planned separation by the second half of 2026, with milestones such as naming the New Corteva CEO and filing Form 10 achieved by 2026-Q2. The trajectory is delivering as planned with no delays reported.
“Corteva remains on track to complete the planned separation in the second half of 2026.”
“On track for 4Q 2026 separation; named New Corteva CEO; filed initial Form 10.”
“On track to complete the planned separation in the second half of 2026.”
“Planned separation in the second half of 2026 is driven by belief it will create long-term value.”
Breaks if: Seed net sales fall below $4.54 billion
Over the next 1 to 3 years, CTVA's performance will depend on management execution and external market conditions. Not investment advice.
